Skip to main content

Table 4 Study 3—Electrophysiology of compound action potential (CAP) waveforms (Fig. 6). Two-way ANOVA results with Holm-Sidak post hoc test and Cohen’s d effect size

From: Acute axon damage and demyelination are mitigated by 4-aminopyridine (4-AP) therapy after experimental traumatic brain injury

Outcome measure F (DFn, DFd); p-value Adjusted p-value Cohen’s d effect size
N1 conduction velocity Interaction:
F1,43 = 0.05412, p = 0.8171
Injury:
F1,43 = 26.20, p < 0.0001
Drug:
F1,43 = 1.056, p = 0.3098
sham veh vs TBI veh:
p = 0.0067
sham 4-AP vs TBI 4-AP:
p = 0.0016
TBI veh vs TBI 4-AP:
ns, p = 0.6182
sham veh vs TBI veh:
d = 1.646
sham 4-AP vs TBI 4-AP:
d = 1.405
TBI veh vs TBI 4-AP:
d = 0.286
N2 conduction velocity Interaction:
F1,43 = 0.2463, p = 0.6222
Injury:
F1,43 = 6.691, p = 0.0132
Drug:
F1,43 = 0.9846, p = 0.3266
sham veh vs TBI veh:
ns, p = 0.1860
sham 4-AP vs TBI 4-AP:
ns, p = 0.4377
TBI veh vs TBI 4-AP:
ns, p = 0.5970
sham veh vs TBI veh:
d = 0.945
sham 4-AP vs TBI 4-AP:
d = 0.582
TBI veh vs TBI 4-AP:
d = 0.577
N2 width
at half-maximum
Interaction:
F1,43 = 0.1562, p = 0.6947
Injury:
F1,43 = 7.827, p = 0.0077
Drug:
F1,43 = 0.1402, p = 0.7099
sham veh vs TBI veh:
ns, p = 0.1601
sham 4-AP vs TBI 4-AP:
ns, p = 0.3032
TBI veh vs TBI 4-AP:
ns, p = 0.9883
sham veh vs TBI veh:
d = 1.003
sham 4-AP vs TBI 4-AP:
d = 0.675
TBI veh vs TBI 4-AP:
d = 0.008
N2 peak to recovery Interaction:
F1,43 = 2.797, p = 0.1017
Injury:
F1,43 = 5.211, p = 0.0275
Drug:
F1,43 = 0.08605, p = 0.7707
sham veh vs TBI veh:
ns, p = 0.0560
sham 4-AP vs TBI 4-AP:
ns, p = 0.6579
TBI veh vs TBI 4-AP:
ns, p = 0.5517
sham veh vs TBI veh:
d = 1.240
sham 4-AP vs TBI 4-AP:
d = 0.171
TBI veh vs TBI 4-AP:
d = 0.365
  1. veh Saline vehicle control; ns: non-significant (p > 0.05). Sham veh vs sham 4-AP ns for each measure (p > 0.5 or higher)